Overview
LabGenius Therapeutics (“LabGenius”) is a next-generation antibody therapeutics company that combines machine learning with automated functional screening to enable the rapid discovery of complex multispecifics. Their lead optimisation platform, EVA™, unlocks high-performing, often non-intuitive molecular designs. EVA™ is both modality and format-agnostic but for their internal pipeline, LabGenius is developing highly selective T-cell engagers for the treatment of solid tumours.
Our Support
SynbiCITE Support
- London Biofoundry Support
- PoC funding
- Lean Launchpad Training
- Biostart Accelerator – participant
Stay up to date with SynbiCITE